Bristol-Myers Squibb GmbH & Co. KGaA
London (ots/PRNewswire) - - Between 15 to 38 percent of HIV-infected persons in Europe do not present for screening and treatment until late in infection.(1) Late presentation has been show to result in increased morbidity(1) and decreasing quality of life.(2,3) Almost three decades after the discovery of HIV/AIDS, and despite big medical advances, there ...
Bristol-Myers Squibb and AstraZeneca
Rome (ots/PRNewswire) - - FOR EUROPEAN MEDICAL MEDIA ONLY - New Data Presented for the First Time at EASD 2008 - Saxagliptin With Metformin as Initial Combination Therapy Lowered A1C - Improvements Demonstrated Across Key Measures of Glucose Control Studied in Treatment-Naïve People With Type 2 ...
Bristol-Myers Squibb and AstraZeneca
Rome (ots/PRNewswire) - - FOR EUROPEAN MEDICAL MEDIA ONLY - New Data Presented for the First Time at EASD 2008 - Saxagliptin With Metformin as Initial Combination Therapy Lowered A1C - Improvements Demonstrated Across Key Measures of Glucose Control Studied in Treatment-Naïve People With Type 2 ...
Chicago and Darmstadt, Germany (ots/PRNewswire) - - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) - Location: Annual Meeting of the American Society of Clinical Oncology (ASCO) 2008, Chicago, ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Paris, and Uxbridge, England (ots/PRNewswire) - The European Commission has granted marketing authorisation for ABILIFY(R) (aripiprazole) in the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in patients who experienced predominantly ...
Sanofi-aventis; Bristol-Myers Squibb
Paris and Princeton, New Jersey (ots/PRNewswire) - - A New Step Forward May Help Increase Appropriate Early Use of Plavix(R) by Simplifying Administration in Acute Coronary Syndrome Patients Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the ...
Brussels, Belgium (ots/PRNewswire) - Unibioscreen S.A., the Brussels specialist oncology company, is pleased to announce that it has succeeded in the closing of a new financing round of EUR 5 million from existing shareholders (ING, Société Générale Asset Management, E-capital, Brustart, UFG-Group and business angels) and from Hunza Ventures. This round brings ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Paris and Uxbridge, England (ots/PRNewswire) - Bristol-Myers Squibb (NYSE: BMY) and Otsuka Pharmaceutical Europe Ltd. announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion on the Marketing Authorisation Application ...
European Liver Patients Association (ELPA)
Brussels, Belgium (ots/PRNewswire) - - European Liver Patients Association Urges People at Risk to get Tested! A report(1) released today by the Eurasian Harm Reduction Network (EHRN)(i) highlights the significant inconsistencies that exist in hepatitis C (HCV) diagnosis and treatment across Europe and ...
Vienna, Austria (ots/PRNewswire) - - New analyses presented in Europe for the first time underscores REACH implications for individuals with leg artery blockages - Findings suggest the need for earlier, more aggressive therapeutic intervention New analyses from the REACH Registry presented at the ...
Barcelona (ots) - New Results Represent Additional Data From a Study Showing Superior Efficacy of ORENCIA or Infliximab Compared to Placebo at Six Months Bristol-Myers Squibb Company (NYSE: BMY) today announced additional study results providing evidence of the efficacy and durability of response of ORENCIA(R) (abatacept) through 12 months in adults with ...
Anti-Tumor Necrosis Factor (TNF) Therapy in Inadequately Responding Rheumatoid Arthritis Patients Barcelona (ots) - According to a new study, it is possible to safely switch directly to ORENCIA® from anti-TNF therapy in rheumatoid arthritis patients who have had an inadequate response to anti-TNF therapy. The results were announced today by Bristol-Myers ...
Chicago (ots/PRNewswire) - - Study Highlights Quality-of-Life Data ALIMTA(R) (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer(i), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). ...
Chicago (ots/PRNewswire) - - Five Phase III Early-Stage Breast Cancer Studies Underway With GEMZAR GEMZAR(R) (gemcitabine HC1 for injection), approved in combination with paclitaxel (Taxol(R)) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study ...
RUEIL- MALMAISON, France, May 23 (ots/PRNewswire) - - Innovative, First-in-Class Medicine Provides New Option for Europeans With Debilitating Disease Bristol-Myers Squibb (NYSE: BMY) announced today the European Commission has granted an approval for ORENCIA(R) (abatacept) for the treatment of rheumatoid ...
Bristol -Myers Squibb Company and Otsuka Pharmaceutical Co. Ltd
Madrid (ots/PRNewswire) - - New Survey Indicates There is Room for Improvement in Physical Health Management Strategies for People Living With Schizophrenia New data presented at the 15th European Congress of Psychiatry (AEP) indicates that the impact of weight gain and metabolic abnormalities associated ...
Paris (ots/PRNewswire) - - New Data Presented at the 48th Annual Meeting and Exposition of the American Society of Hematology (ASH) For Non-US Journalists Only New data presented today showed that a substantial number of patients with chronic-phase chronic myelogenous leukaemia (CML) resistant to ...
Paris (ots/PRNewswire) - - Photographers From Across Europe Invited to Participate in Contest to Fight Stigma and Discrimination of HIV/AIDS Patients. Bristol-Myers Squibb announced today - World AIDS Day - the launch of the fourth edition of the One Vision European photography competition, an initiative that is literally helping to change the image of HIV and AIDS across Europe. "People are living longer ...
Paris, November 22 (ots/PRNewswire) - - New Hope for CML and Ph+ ALL Patients who Face Resistance or Intolerance to Current Therapies For Non-US Journalists Only Today, the European Commission approved SPRYCEL(TM) (dasatinib, formerly known as BMS-354825) for the treatment of adults with chronic, ...
Paris, November 9 (ots/PRNewswire) - - Data to be Presented at Upcoming American College of Rheumatology Annual Meeting Bristol-Myers Squibb Company (NYSE: BMY) today announced that two-year data from three Phase III pivotal trials demonstrate the long-term efficacy of abatacept in adult patients with moderate to severe rheumatoid arthritis (RA) who have ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Bristol-Myers Squibb Medical Imaging
Journalists and other readers should disregard the news release "Bristol-Myers Squibb Medical Imaging Receives European Commission Marketing Authorisation for Its Ultrasound Contrast Agent LUMINITY(TM) (perflutren lipid microsphere)" NYSE:BMY, issued earlier today. The release was issued prematurely by PR Newswire. ots Originaltext: Bristol-Myers Squibb Medical ...
Bristol-Myers Squibb Medical Imaging
N. Billerica, Massachusetts (ots/PRNewswire) - Bristol-Myers Squibb Medical Imaging announced today that the European Commission has granted marketing authorisation for LUMINITY(TM), an ultrasound contrast agent, for use in patients with suboptimal echocardiograms who have suspected or established ...
Sanofi-aventis; Bristol-Myers Squibb
Paris (ots/PRNewswire) - - PLAVIX indication expanded to include patients with any acute coronary syndromes (ACS) - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and Bristol-Myers Squibb Company (NYSE: BMY) announced today that the European Commission has granted a new indication for the antiplatelet ...
Paris (ots/PRNewswire) - Bristol-Myers Squibb announced today that the European Commission has granted an approval for BARACLUDE(R) (entecavir) for the treatment of chronic hepatitis B virus infection. BARACLUDE(R) is an oral antiviral therapy specifically designed to block the replication of hepatitis B ...
Amsterdam (ots/PRNewswire) - Data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress in Amsterdam show that 3 years of treatment with the selective co-stimulation modulator abatacept, maintains improvements in Rheumatoid Arthritis (RA) symptoms, physical function, disease activity ...
Amsterdam (ots/PRNewswire) - New data presented at the 2006 European League Against Rheumatism (EULAR) Annual Congress from the one-year open label extension of the 6-month ATTAIN trial (Abatacept Trial in Treatment of Anti-TNF INadequate responders)[1] in which all patients were treated with abatacept, a ...
Vienna, Austria (ots/PRNewswire) - Bristol-Myers Squibb Company (NYSE: BMY) today announced 96-week clinical trial results demonstrating that entecavir maintains more viral load suppression compared to lamivudine in nucleoside-naive, chronic hepatitis B e-antigen-negative (HBeAg-) patients. Data ...
Indianapolis (ots/PRNewswire) - - Enzastaurin Study Enrolling Patients with Glioblastoma One of the deadliest and rarest forms of cancer is the focus of a Phase III study initiated by Eli Lilly and Company today. Enzastaurin, an investigational, targeted, oral agent, will be evaluated at more than 100 sites worldwide for the treatment of relapsed glioblastoma multiforme (GBM), an aggressive and malignant form ...
Dublin, Ireland, November 21 (ots/PRNewswire) - - Additional Data Provide Further Guidance on Maximizing Treatment Response with APTIVUS(R) New data presented at the 10th European AIDS Conference (EACS) in Dublin demonstrate that through 48 weeks, APTIVUS(R) (tipranavir) provides a convincing and durable benefit, achieving and maintaining a superior treatment response in patients with resistant HIV.(1) ...